Page 85 of 1,034: studies 841 to 850 of 10,336, newest first. Back to the depression overview
Quarterly Journal of Child Mental Health July 1, 2025 Mozhgan Mazaheri, Nasrin Saeedi Farid, Narges Asgari Toorzani et al.
Background and Purpose: Anxiety disorders in children are among the most prevalent mental health issues, with widespread negative impacts on their emotional, cognitive
Mindfulness July 1, 2025 Maggie Lawrence, Bridget Davis, Naomi E. Clark et al.
Abstract Objectives The purpose of this study was to assess feasibility and acceptability of a stroke-specific mindfulness-based intervention called Helping Ease Anxiety and Depression after Stroke (HEADS: UP). Method This study was a mixed-methods pilot randomized controlled trial comparing HEADS: UP to treatment as usual (TAU). HEADS: UP is a 9-week mindfulness intervention for stroke...
Mindfulness July 1, 2025 Jonathan Hamilton, Kate Brennan, Daniel Brown et al.
Abstract Objectives Mindfulness training has been shown to be helpful in the treatment of depression. However, standard mindfulness-based interventions (MBIs) are still not widely available and sustaining a mindfulness practice can be difficult for patients with current depression. Alternative delivery formats may serve to address these problems. This study tested the acceptability,...
Cureus July 1, 2025 Elizabeth Francis
Treatment-resistant depression (TRD) remains a significant clinical challenge, often accompanied by polypharmacy and comorbid anxiety or trauma-related disorders. This report describes a 37-year-old male with longstanding major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and social anxiety disorder who demonstrated limited response to traditional pharmacologic strategies,...
Indian Journal of Pharmacology July 1, 2025 J V Ashwin, Mohit Kumar Shahi, Astha Singh et al.
This network meta-analysis evaluated the efficacy and safety of the dextromethorphan-bupropion combination (AXS-05) in treating major depressive disorder (MDD). Data were retrieved from multiple databases, including PubMed, Embase, Scopus, Google Scholar, and ClinicalKey, yielding 60 records. After removing duplicates and excluding irrelevant studies, such as reviews, case reports, posters, and...
Biological Psychiatry Global Open Science July 1, 2025 Paul S Myles, Jayashri Kulkarni, Jessica Kasza et al.
Nitrous oxide ("laughing gas") is an NMDA receptor antagonist. In the current study, our aim was to investigate the efficacy, safety, and likely optimal dose of nitrous oxide in adults with major depressive disorder (MDD). In this phase 2b randomized, double-blind trial, 81 patients with MDD were allocated on a 1:1 basis to receive nitrous oxide or oxygen/air (control); the nitrous group was...
BILT Student Research Journal 2025 - Issue 6 July 1, 2025 Sophie Höfels 1 citation
The novel antidepressant ketamine has been shown to achieve what most classic antidepressants, such as Selective Serotonin Reuptake Inhibitors, have not been able to. A rapid onset of symptomatic improvement across multiple domains; mood, anhedonia, and suicidal ideation. The exact neuropsychopharmacological mechanisms of this unique phenomenon are still unknown, although many theories are...
Molecular Psychiatry July 1, 2025 Rebecca Harding, Neomi Singer, Matthew B. Wall et al. correction
The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article...
Journal of Psychopharmacology July 1, 2025 Ryan M Brudner, Erica Kaczmarek, Marc G Blainey et al. 3 citations
Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a key aspect of the subjective effects...
European Archives of Psychiatry and Clinical Neuroscience July 1, 2025 Erhan Kavakbasi, Kevin Rosemann, Mert Yilmaz et al. 2 citations
Intranasal esketamine (ESK) is a novel therapy option in patients with treatment-resistant depression (TRD). Patients with a history of electroconvulsive therapy (ECT) non-response (ECT+) in the current episode have usually been excluded from previous studies. Data on the effectiveness of ESK in ECT non-responders are sparse. In this retrospective study, we investigated the effectiveness of...